Viking Therapeutics, Inc. Aktie News

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Hubert C. C...

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company...

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13 Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second po...

Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging global expansion and late-stage development to compete with incumbents Lilly and Novo Nordisk. Nothing is over just yet. Phase 3 for VK2735 Oral is set for late 2026, with initial commercial ramp expecte...

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announ...

Buy the story, sell the news. That's a reasonable explanation for why Viking Therapeutics NASDAQ: VKTX fell over 3% the day the company delivered its Q1 2026 earnings report.

Viking Therapeutics, Inc. remains a hold as competitive pressure mounts in the GLP-1 obesity/diabetes space, with its lead VK2735 candidate lagging larger peers. VKTX's Phase 3 VANQUISH studies are fully enrolled, but pivotal data are not expected (by me) until late 2027/early 2028, making near-term catalysts limited. The upcoming Q3 maintenance study readout is a potential wildcard; positive r...

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript